Mechanism of Action (MOA) Videos
This multimedia content is made available for HCPs specializing in oncology for learning and information purposes only to address the need of the medical community to better understand investigational interventions and the physiology of disease
View videos from GSK oncology on proposed mechanism of action of GSK compounds
Belantamab Mafodotin*
Anti-BCMA immunoconjugate
Learn about how belantamab mafodotin binds to B-cell maturation antigen and eliminates myeloma cells by a multimodal mechanism.
*In-license or other partnership with third party
Letetresgene Autoleucel*
NY-ESO-1 TCR T Cell
Learn about NY-ESO-1 and LAGE-1a which are highly homologous immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses.
*In-license or other partnership with third party.
Cobolimab
Anti-TIM-3 Antibody
Learn about Cobolimab a selective humanized anti-TIM-3 IgG4 monoclonal antibody that enhances T-cell activation.
Dostarlimab
Anti-PD-1 antibody
Learn about the programmed cell death protein 1 (PD-1), an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cell-mediated immune response
Niraparib
PARP inhibitor
Learn about the Poly ADP ribose polymerases (PARPs) family of enzymes which are involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. PARP inhibition induces cell death through synthetic lethality.
NX-CA-AOU-WCNT-210001 | February 2022
